Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342826 | 0.68 | P2RY6 (0.33) | — | |
| SCHEMBL11779705 | 0.64 | — | — | |
| SCHEMBL11993892 | 0.63 | OXTR (0.37) | OXTRNISCHGAANPSR1 | |
| SCHEMBL20872264 | 0.62 | MAOA (0.37) | NISCH | |
| SCHEMBL11810865 | 0.60 | ABCG2 (0.34) | — | |
| SCHEMBL10771985 | 0.59 | CA12 (0.37) | GAA | |
| SCHEMBL574744 | 0.58 | OXTR (0.47) | OXTRGAANPSR1PARP1 | |
| SCHEMBL3755519 | 0.58 | — | — | |
| SCHEMBL19312038 | 0.58 | OXTR (0.42) | OXTRNISCHGAANPSR1 | |
| SCHEMBL14304447 | 0.57 | CYP1A2 (0.33) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311150-A1 | Novel sequences encoding hepatitis C virus glycoproteins | DUMONCEAUX JULIE | 2008-12-18 | — | — | US | disclosed |
| US-7361503-B2 | Sequences encoding hepatitis C virus glycoproteins | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060292151-A1 | L-SIGN polymorphisms and methods involving use of same | PROGENICS PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-20050266400-A1 | Novel sequences encoding hepatitis C virus glycoproteins | PROGENICS PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266400-A1 | Novel sequences encoding hepatitis C virus glycoproteins | HAVCR2, EEA1, SELPLG | OXTR 3456/4885NISCH 4746/4885GAA 777/4885 |
| US-20080311150-A1 | Novel sequences encoding hepatitis C virus glycoproteins | HAVCR2, EEA1, SELPLG | OXTR 3456/4885NISCH 4746/4885GAA 777/4885 |
| US-20060292151-A1 | L-SIGN polymorphisms and methods involving use of same | HAVCR2, SELL, SELPLG | OXTR 2896/4885NISCH 2313/4885GAA 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.